Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

NCT06874933 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

HR+/HER2- Breast Cancer

Interventions

DRUG: Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart

Sponsor

First Affiliated Hospital of Zhejiang University